Contributor Disclosures for Polycythemia, Secondary

Role Name Disclosure Details Author  Emmanuel C Besa, MD, Professor, Department of Medicine, Division of Hematologic Malignancies, Kimmel Cancer Center, Thomas Jefferson University Nothing to disclose Details Coauthor  Ulrich Woermann, MD, Consulting Staff, Division of Instructional Media, Institute for Medical Education, University of Bern, Switzerland Nothing to disclose Details Medical Editor  Karen Seiter, MD, Professor, Department of Internal Medicine, Division of Oncology/Hematology, New York Medical College Novartis Celgene Schering Details Pharmacy Editor  Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine Nothing to disclose Details Managing Editor  Ronald A Sacher, MB, BCh, MD, FRCPC, Director of the Hoxworth Blood Center, Professor, Departments of Internal Medicine and Pathology, University of Cincinnati Medical Center Glaxo Smith Kline Talecris Details CME Editor  Rajalaxmi McKenna, MD, FACP, Consulting Staff, Department of Medicine, Southwest Medical Consultants, SC, Good Samaritan Hospital, Advocate Health Systems Nothing to disclose Details Chief Editor  Michael E Zevitz, MD, Assistant Professor of Medicine, Finch University of the Health Sciences, The Chicago Medical School; Consulting Staff, Private Practice Nothing to disclose Details CONTRIBUTOR DISCLOSURE FORM Contributor Name: Emmanuel C Besa  DECLARATION STATEMENT I and/or my spouse/partner have no financial interest with any organization that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity. I and/or my spouse/partner have a financial interest/arrangement with one or more organization(s), including but not limited to the organization(s) supporting this activity, that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity. COMMERCIAL INTEREST (Name of Organization) Self Spouse/ Partner NATURE OF RELEVANT FINANCIAL RELATIONSHIP What was received?* For what role?** Off label or investigational use of medication Revlimid in non-5q- syndrome MDSExjade in transfusion overload in MDS Contributor Disclosure Contributor: Contributor Disclosure: Ulrich Woermann, Coauthor  The contributor discloses no conflict of interest.  CONTRIBUTOR DISCLOSURE FORM Contributor Name: Karen Seiter  DECLARATION STATEMENT I and/or my spouse/partner have no financial interest with any organization that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity. I and/or my spouse/partner have a financial interest/arrangement with one or more organization(s), including but not limited to the organization(s) supporting this activity, that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity. COMMERCIAL INTEREST (Name of Organization) Self Spouse/ Partner NATURE OF RELEVANT FINANCIAL RELATIONSHIP What was received?* For what role?** Novartis Honoraria Speaking and teaching   Celgene Honoraria Speaking and teaching   Schering Honoraria Speaking and teaching   Off label or investigational use of medication CONTRIBUTOR DISCLOSURE FORM Contributor Name: Francisco Talavera  DECLARATION STATEMENT I and/or my spouse/partner have no financial interest with any organization that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity. I and/or my spouse/partner have a financial interest/arrangement with one or more organization(s), including but not limited to the organization(s) supporting this activity, that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity. COMMERCIAL INTEREST (Name of Organization) Self Spouse/ Partner NATURE OF RELEVANT FINANCIAL RELATIONSHIP What was received?* For what role?** Off label or investigational use of medication CONTRIBUTOR DISCLOSURE FORM Contributor Name: Ronald A Sacher  DECLARATION STATEMENT I and/or my spouse/partner have no financial interest with any organization that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity. I and/or my spouse/partner have a financial interest/arrangement with one or more organization(s), including but not limited to the organization(s) supporting this activity, that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity. COMMERCIAL INTEREST (Name of Organization) Self Spouse/ Partner NATURE OF RELEVANT FINANCIAL RELATIONSHIP What was received?* For what role?** Glaxo Smith Kline Honoraria Speaking and teaching   Talecris Honoraria Board membership   Off label or investigational use of medication CONTRIBUTOR DISCLOSURE FORM Contributor Name: Rajalaxmi McKenna  DECLARATION STATEMENT I and/or my spouse/partner have no financial interest with any organization that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity. I and/or my spouse/partner have a financial interest/arrangement with one or more organization(s), including but not limited to the organization(s) supporting this activity, that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity. COMMERCIAL INTEREST (Name of Organization) Self Spouse/ Partner NATURE OF RELEVANT FINANCIAL RELATIONSHIP What was received?* For what role?** Off label or investigational use of medication CONTRIBUTOR DISCLOSURE FORM Contributor Name: Michael E Zevitz  DECLARATION STATEMENT I and/or my spouse/partner have no financial interest with any organization that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity. I and/or my spouse/partner have a financial interest/arrangement with one or more organization(s), including but not limited to the organization(s) supporting this activity, that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity. COMMERCIAL INTEREST (Name of Organization) Self Spouse/ Partner NATURE OF RELEVANT FINANCIAL RELATIONSHIP What was received?* For what role?** Off label or investigational use of medication